Drug class in one race
HER2 drugs for HR+/HER2- Metastatic Breast Cancer
4 tracked HER2 drugs in the HR+/HER2- Metastatic Breast Cancer race. The class explanation lives on the HER2 page; the full indication pipeline across every mechanism is on the HR+/HER2- Metastatic Breast Cancer page.
1 approved / phase 43 Phase 3
Head-to-head evidence: DB-1303 vs Disitamab Vedotin · DB-1303 vs Trastuzumab Deruxtecan · Disitamab Vedotin vs Trastuzumab Deruxtecan · Disitamab Vedotin vs Trastuzumab rezetecan · Trastuzumab Deruxtecan vs Trastuzumab rezetecan